Hytrin (Terazosin)

Terazosin selectively blocks alpha‑1 adrenergic receptors on vascular smooth muscle and prostate tissue. By preventing norepinephrine from binding, it causes vasodilation, reducing peripheral resistance and blood pressure. In the prostate, the same blockade relaxes smooth muscle, decreasing urinary obstruction associated with BPH.

The appropriate dose of Hytrin is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and any concurrent medications. Dosage adjustments are made according to clinical judgment and patient monitoring.

Safety data for Terazosin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers will evaluate the risk‑benefit profile before prescribing to pregnant or nursing women.

To request Hytrin, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Hytrin belongs to the selective alpha‑1 blocker class, which lowers blood pressure primarily through vasodilation. Unlike ACE inhibitors or calcium‑channel blockers, it does not affect the renin‑angiotensin system or calcium channels. Its dual action on prostate smooth muscle also makes it useful for BPH, a benefit not shared by many other antihypertensives.

Hytrin tablets should be stored at room temperature, below 25 °C. Keep them in the original packaging to protect from moisture and light, and store out of reach of children. Do not refrigerate or freeze the product.

Hytrin is taken orally, usually as a whole tablet with a glass of water. It can be taken with or without food, but patients should follow the specific instructions provided by their prescriber to maintain consistent absorption and effect.

The most serious risks include severe hypotension, which can lead to fainting or shock, and rare events such as priapism or serious allergic reactions (e.g., angioedema). Patients should seek immediate medical attention if they experience sudden dizziness, prolonged erection, or signs of an allergic response.

Hytrin is contraindicated in patients with known hypersensitivity to Terazosin or any component of the formulation. It should also be avoided in individuals with severe orthostatic hypotension, recent myocardial infarction, or those taking medications that may cause dangerous additive blood‑pressure lowering effects without close monitoring.